GSK Stock in Brief

Healthcare company GSK has moved 1.2% so far today on a volume of 3,084,852, compared to its average of 6,641,414. In contrast, the S&P 500 index moved 0.8%

GSK trades -18.43% away from its average analyst target price of $44.32 per share. The 3 analysts following the stock have set target prices ranging from $33 to $63.75, and on average have given GSK a rating of hold.

Anyone interested in buying GSK should be aware of the facts below:

  • GSK 's Graham number (a purchase price with a built-in margin of safety) is $16.54, which is 118.5% away from its current price

  • GSK has moved -16.8% over the last year, and the S&P 500 logged a change of -13.9%

  • Based on its trailing earning per share of 2.68, GSK has a trailing 12 month Price to Earnings (P/E) ratio of 13.5 while the S&P 500 average is 15.97

  • GSK has a forward P/E ratio of 9.8 based on its forward 12 month price to earnings (Eps) is $3.69 per share

  • The company has a price to earnings growth (PEG) ratio of 0.94 -- a number near or below 1 signifying that GSK is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 8.0 compared to its sector average of 4.07

  • GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

  • Based in Brentford, the company has 90,096 full time employees and a market cap of $74,534,068,224. GSK currently returns an annual dividend yield of 2.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.